Clinical trials
Lymphoma, Mantle-Cell trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 1 |
| 2018 | 3 |
| 2020 | 4 |
| 2021 | 6 |
| 2022 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 26 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 5 |
| Chinese PLA General Hospital | 4 |
| Peking University Third Hospital | 3 |
| Shandong Provincial Hospital | 2 |
| Sun Yat-sen University | 2 |
| Xinqiao Hospital of Chongqing | 2 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 1 |
| He Huang | 1 |
| Qilu Puget Sound Biotherapeutics (dba Sound Biologics) | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lymphoma, Mantle-Cell | 26 |
| Lymphoma, Large B-Cell, Diffuse | 15 |
| Lymphoma, Follicular | 14 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 |
| Hematologic Neoplasms | 5 |
| Leukemia, Prolymphocytic | 3 |
| Leukemia, Prolymphocytic, B-Cell | 3 |
| Lymphoma, B-Cell | 3 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 |
| Burkitt Lymphoma | 2 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.